STOCK TITAN
  1. Home
  2. Sec-filings
  3. TLSA
  4. [6-K] Tiziana Life Sciences Ltd Current Report (Foreign Issuer)

[6-K] Tiziana Life Sciences Ltd Current Report (Foreign Issuer)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Tiziana Life Sciences filed a Form 6-K to announce that it will present at the Jefferies Healthcare Conference in New York City. Chief Executive Officer Ivor Elrifi and Chief Operating and Financial Officer Keeren Shah will give a corporate presentation covering recent clinical and corporate developments.

The company highlights intranasal foralumab, its lead fully human anti-CD3 monoclonal antibody, which is being evaluated in non-active secondary progressive multiple sclerosis, including an expanded access program and an ongoing Phase 2a clinical trial. Management plans to discuss strategic direction and upcoming milestones with institutional investors during the conference.

Positive

  • None.

Negative

  • None.
Conference presentation date June 4, 2026 Jefferies Healthcare Conference presentation slot
Presentation time window 10:30–11:00 AM Jefferies Healthcare Conference session
Patients dosed in EA program 14 patients Non-active secondary progressive multiple sclerosis expanded access program
Clinical response window 6 months Improvement or stability observed within this period in EA program
Phase of controlled trial Phase 2a Randomized, double-blind, placebo-controlled trial in na-SPMS (NCT06292923)
intranasal foralumab medical
"developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody"
Intranasal foralumab is an experimental antibody medication given as a spray or drops into the nose that aims to change how the immune system behaves rather than attack a virus directly. Investors care because results from trials, safety findings, and regulatory decisions determine whether this approach can become a marketed therapy, affecting a company’s future sales, development costs and competitive position — similar to betting on a new product that could reshape a company’s revenue stream.
anti-CD3 monoclonal antibody medical
"foralumab, a fully human anti-CD3 monoclonal antibody, is a biologic candidate"
A lab-made antibody engineered to attach to CD3, a protein found on T cells, so it can change how those immune cells behave. Investors care because these drugs can act like a targeted brake on an overactive immune system—useful for autoimmune disease, transplant rejection or as part of cancer therapies—but they also carry clinical trial, safety and regulatory risks that determine commercial success.
Expanded Access (EA) Program regulatory
"dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328)"
Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial medical
"currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial"
non-active secondary progressive multiple sclerosis medical
"patients with non-active secondary progressive multiple sclerosis (NCT06292923)"
forward-looking statements regulatory
"Certain statements made in this announcement are forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What did Tiziana Life Sciences (TLSA) announce in this Form 6-K?
Tiziana Life Sciences announced it will present at the Jefferies Healthcare Conference in New York City. Senior executives will deliver a corporate presentation highlighting recent clinical data, corporate updates, strategic direction, and upcoming milestones for its lead candidate, intranasal foralumab.

When and where will Tiziana Life Sciences present at the Jefferies Healthcare Conference?
Tiziana will present at the Jefferies Healthcare Conference on Thursday, June 4, 2026, from 10:30 to 11:00 AM in New York. The presentation will be followed by a question-and-answer session with institutional investors attending the event.

What is Tiziana Life Sciences’ lead drug candidate, intranasal foralumab?
Intranasal foralumab is a fully human anti-CD3 monoclonal antibody designed for nasal delivery. It has been shown to stimulate regulatory T cells and is being developed as a novel immunomodulatory approach for neuroinflammatory and neurodegenerative diseases such as non-active secondary progressive multiple sclerosis.

What clinical data on foralumab did Tiziana Life Sciences reference?
Tiziana reported that 14 patients with non-active secondary progressive multiple sclerosis have been dosed in an expanded access program, with improvement or stability of disease seen within six months in all patients. Foralumab is also being studied in an ongoing Phase 2a randomized, placebo-controlled trial.

How is intranasal foralumab being studied in multiple sclerosis patients?
Intranasal foralumab is being evaluated in non-active secondary progressive multiple sclerosis in two settings: an open-label, intermediate-sized expanded access program and a Phase 2a randomized, double-blind, placebo-controlled, multicenter, dose-ranging clinical trial identified as NCT06292923.

How does Tiziana Life Sciences describe its broader drug development strategy?
Tiziana describes itself as a clinical-stage biopharmaceutical company focused on breakthrough therapies using alternative routes of immunotherapy. Its nasal delivery technology aims to improve efficacy, safety, and tolerability versus intravenous delivery, with patents granted and additional applications pending to support a broader pipeline.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

May 2026

 

 

 

Commission File Number:  001-38723

 

 

 

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

9th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

  

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 


 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 

On May 28, 2026, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing, that it will present at the Jefferies Healthcare Conference taking place in New York City. Ivor Elrifi, Chief Executive Officer and Keeren Shah, Chief Operating and Financial Officer of Tiziana Life Sciences, will deliver a corporate presentation highlighting the Company’s recent clinical and corporate updates.

 

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

 

1

 

 


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  TIZIANA LIFE SCIENCES LTD
       
Date: May 28, 2026 By: /s/ Keeren Shah
    Name:  Keeren Shah
    Title: Chief Financial Officer

 

2

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Tiziana Life Sciences LTD Press Release, dated May 28, 2026

 

 

3

 

 

Exhibit 99.1

 

 

 

Tiziana Life Sciences to Present at the Jefferies Healthcare Conference in New York

 

BOSTON, MA, May 28, 2026 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that it will present at the Jefferies Healthcare Conference taking place in New York City. Ivor Elrifi, Chief Executive Officer and Keeren Shah, Chief Operating and Financial Officer of Tiziana Life Sciences, will deliver a corporate presentation highlighting the Company’s recent clinical and corporate updates.

 

Presentation Details:

Event: Jefferies Healthcare Conference

Date: Thursday, June 4, 2026

Time: 10:30 – 11:00 AM ET

Location: New York, NY

 

The presentation will be followed by a question-and-answer session with institutional investors.

 

“We are pleased to participate in the Jefferies Healthcare Conference and look forward to sharing our recent progress with the investment community,” said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. “This is an important time for the Company as we advance multiple clinical programs, and we welcome the opportunity to provide an update on our strategic direction and upcoming milestones.”

 

About Foralumab

 

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biologic candidate that has been shown to stimulate T regulatory cells when dosed intranasally. Currently, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

 

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2],[3]

 

 

[1]https://www.pnas.org/doi/10.1073/pnas.2220272120
[2]https://www.pnas.org/doi/10.1073/pnas.2309221120
[3]https://www.neurology.org/doi/10.1212/NXI.0000000000200543

 

 

 

About Tiziana Life Sciences

 

Tiziana is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

 

For more information about Tiziana and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

 

Forward-Looking Statements

 

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Tiziana's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Tiziana's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Tiziana cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of Tiziana only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Tiziana will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

For further inquiries:

 

Tiziana Life Sciences Ltd

Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases